- Home
- ABUS vs JELD Comparison
ABUS vs JELD Comparison
Compare ABUS & JELD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- JELD
- Stock Information
- Founded
- ABUS N/A
- JELD 1960
- Country
- ABUS United States
- JELD United States
- Employees
- ABUS N/A
- JELD N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- JELD Forest Products
- Sector
- ABUS Health Care
- JELD Basic Materials
- Exchange
- ABUS Nasdaq
- JELD Nasdaq
- Market Cap
- ABUS 629.1M
- JELD 707.4M
- IPO Year
- ABUS N/A
- JELD 2017
- Fundamental
- Price
- ABUS $3.42
- JELD $5.95
- Analyst Decision
- ABUS Strong Buy
- JELD Hold
- Analyst Count
- ABUS 4
- JELD 8
- Target Price
- ABUS $5.50
- JELD $12.44
- AVG Volume (30 Days)
- ABUS 646.4K
- JELD 1.1M
- Earning Date
- ABUS 03-03-2025
- JELD 02-17-2025
- Dividend Yield
- ABUS N/A
- JELD N/A
- EPS Growth
- ABUS N/A
- JELD N/A
- EPS
- ABUS N/A
- JELD N/A
- Revenue
- ABUS $6,742,000.00
- JELD $3,775,600,000.00
- Revenue This Year
- ABUS N/A
- JELD N/A
- Revenue Next Year
- ABUS N/A
- JELD N/A
- P/E Ratio
- ABUS N/A
- JELD N/A
- Revenue Growth
- ABUS N/A
- JELD N/A
- 52 Week Low
- ABUS $2.30
- JELD $5.79
- 52 Week High
- ABUS $4.72
- JELD $21.75
- Technical
- Relative Strength Index (RSI)
- ABUS 54.07
- JELD 25.37
- Support Level
- ABUS $3.24
- JELD $5.79
- Resistance Level
- ABUS $3.44
- JELD $9.15
- Average True Range (ATR)
- ABUS 0.12
- JELD 0.53
- MACD
- ABUS 0.01
- JELD -0.33
- Stochastic Oscillator
- ABUS 55.56
- JELD 4.56
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
About JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.